Red clover-derived isoflavones and mammographic breast density: a double blind, randomised, placebo-controlled trial

Submission date	Recruitment status	Prospectively registered
30/01/2004	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/01/2004	Completed	[X] Results
Last Edited	Condition category	Individual participant data
02/10/2012	Cancer	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Sheila A. Bingham

Contact details

MRC Dunn Human Nutrition Unit Cambridge United Kingdom CB2 2XY

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Study objectives

To determine the effects of taking a red clover-derived isoflavone supplement daily for one year on mammographic breast density. Effects on oestradiol, follicle-stimulating hormone (FSH), luteinising hormone (LH), lymphocyte tyrosine kinase activity and menopausal symptoms were also assessed.

Ethics approval required

Old ethics approval format

Ethics approval(s)

All study procedures were approved by the Dunn Human Nutrition Unit Ethics Committee, and the Cambridge Local Research Ethics Committee.

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Red clover-derived isoflavone tablet (26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein) or placebo.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Red clover-derived isoflavone supplement

Primary outcome measure

Change in:

- 1. Mammographic breast density
- 2. Serum oestradiol, FSH and LH
- 3. Menopausal symptoms
- 4. Lymphocyte tyrosine kinase activity

Measured from baseline to 12 months.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/05/1997

Completion date

31/12/1999

Eligibility

Key inclusion criteria

- 1. Women aged 49 65 years
- 2. Wolfe's P2 or DY (dense parenchyma) mammographic breast patterns

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

205

Key exclusion criteria

Not provided at time of registration.

Date of first enrolment

01/05/1997

Date of final enrolment

31/12/1999

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Dunn Human Nutrition Unit Cambridge United Kingdom CB2 2XY

Sponsor information

Organisation

Medical Research Council (UK)

Sponsor details

20 Park Crescent London United Kingdom W1B 1AL

Sponsor type

Research council

ROR

https://ror.org/03x94j517

Funder(s)

Funder type

Industry

Funder Name

Novogen Ltd (Australia)

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2004		Yes	No